611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net
Cancer
Resources
Basic InformationLatest News
Screening Often Misses Endometrial Cancer in Black WomenLong Distance to Care Can Mean Worse Outcomes for Young Cancer PatientsAlcohol Tied to 740,000 Cancer Cases Worldwide in 2020Cancer Survivors Fared Better Financially After ObamacarePandemic Delays in Screening Mean More Breast Cancer Deaths Ahead: StudyObese Men May Have Better Survival With Advanced Prostate CancerMost Cancer Screenings Make Big Rebound After Pandemic DeclineAdding MRI to Screening Can Cut Prostate Cancer Overdiagnosis in HalfU.S. Deaths From Cancer Continue to DeclineAlmost All Cancer Patients Respond Well to COVID-19 VaccinesCould Too Many Antibiotics Raise Your Odds for Colon Cancer?Too Little Sunlight, Vitamin D May Raise Colon Cancer RiskShining a Light on SunscreensGap in Breast Cancer Survival for Black, White Patients Shrinks, But Not by EnoughCost a Barrier to Cervical Cancer Screening for Many U.S. WomenMost Americans Don't Follow Diets That Could Prevent CancerAHA News: Women With Heart Failure From Breast Cancer Treatment May Fare Better Than Previously ThoughtWomen's Cancer Screenings Plummeted During PandemicYoung Cancer Survivors Vulnerable to COVID, But Often Shun VaccineSome Myeloma Patients Get No Protection From COVID-19 VaccinesBlack Men Less Likely to Get Best Prostate Cancer TreatmentsCould Home Test for Colon Cancer Mean a Big Medical Bill to Come?Heart Failure Patients May Be at Higher Cancer RiskCould a DNA Blood Test Spot a Range of Hidden Cancers?For People With Heart Failure, Statins May Lower Cancer Risk TooMany 'High-Risk' Americans Unconcerned About Skin Cancer: PollSurvivors' Plasma Helps Blood Cancer Patients Battle COVID-19Race Doesn't Affect Risk for Genes That Raise Breast Cancer RiskHealthy Levels of Vitamin D May Boost Breast Cancer OutcomesStudy Pinpoints Cancer Patients at Highest Risk From COVIDCan You Keep Your Bladder After Bladder Cancer Strikes?Breast Cancer's Spread Is More Likely in Black Women, Study FindsNewly Approved Drug Fights Lung Cancer Tied to Certain GenesDrug Lynparza Could Help Fight Some Early-Stage Breast CancersTargeted Radiotherapy Might Help Men Battling Advanced Prostate CancerOut-of-Pocket Costs Delay Cancer Follow-Up Care, Even for the InsuredDon't Delay Lung Cancer Surgery, Study SuggestsModerate Use of Hair Relaxers Won't Raise Black Women's Cancer Risk: StudyFaulty Gene Could Raise Vulnerability to Asbestos-Linked CancerColonoscopy After 75: A Potential Lifesaver for MostBreast Cancer Treatments Don't Raise COVID RisksImmunotherapy Drug Can Beat Back Early-Stage Lung CancerKey Factors That Raise Your Odds for Early-Onset Colon CancerHPV Vaccination Is Lowering U.S. Cervical Cancer RatesAs Medicaid Access Expands, So Does Cancer SurvivalMS May Not Affect Breast Cancer PrognosisGet First Colonoscopy at 45, not 50: U.S. Expert PanelMelanoma Can Strike Your Nails: Here's How to CheckGene-Targeted Drug Shows Promise Against a Form of Pancreatic CancerObesity Raises Odds for Many Common Cancers
LinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Pain Management

Gene-Targeted Drug Shows Promise Against a Form of Pancreatic Cancer

HealthDay News
by By Ernie Mundell and Steven Reinberg HealthDay Reporters
Updated: May 11th 2021

new article illustration

TUESDAY, May 11, 2021 (HealthDay News) -- There may be new hope for patients with a subset of pancreatic cancers tied to certain genetic mutations, a new study finds.

The study involving 42 patients found that a "PARP inhibitor" drug called rucaparib (Rubraca), may replace chemotherapy in the up to 8% of pancreatic cancer patients whose tumors are marked by BRCA1, BRCA2 and PALB2 genetic mutations.

Two-thirds of pancreatic cancer patients with these tumor mutations experienced a halt in the growth of their cancer, or even tumor shrinkage, after switching from chemotherapy to rucaparib as a maintenance therapy, researchers found. The study was partly funded by Clovis Oncology, which makes rucaparib.

Rucaparib is a targeted therapy given as a pill. It's currently approved by the U.S. Food and Drug Administration as a maintenance therapy for patients with recurrent ovarian and fallopian tube cancer and prostate cancer, but not yet for pancreatic cancer. Maintenance therapy refers to ongoing therapies after initial, first-line cancer treatment has been received.

"This is another step forward for PARP inhibitors and for the treatment of tough-to-treat pancreas tumors," said study author Dr. Kim Reiss, an assistant professor of hematology-oncology at University of Pennsylvania's Perelman School of Medicine.

"It's a safe option that not only has the potential to maintain responses, but also shrink pancreatic tumors and, in some cases, achieve complete responses for those carrying these mutations," Reiss added in a university news release.

Arnold Simon, age 71, was one of the patients in the trial. He was diagnosed with metastatic pancreatic cancer in 2016 and discovered he had the BRCA2 mutation. Simon has taken rucaparib for more than three years and since then, all of his last 16 CT scans have been clear, with no signs of cancer.

"The biggest benefit of being on the PARP inhibitor is that it is pills only, and the side effects have been minimal," Simon said in the release. "I don't have to go down and sit and have chemo dripped for six hours into me. As far as I'm concerned, for me, there's nothing better than what I'm currently on."

Lydia Henson, 56, was diagnosed with metastatic pancreatic cancer in 2014 and treated with chemotherapy for years before discovering she had the PALB2 mutation. She has been on the PARP inhibitor for 18 months, with no signs of active cancer.

But not all patients will have such positive responses: Of the 42 patients with advanced pancreatic cancer in the new trial, 12 had a partial response and three had a complete response. The results were published online May 10 in the Journal of Clinical Oncology.

In all, two-thirds (66.7%) of the patients had a complete response, partial response or stable disease over a median of 17 months.

Survival with no progression of the cancer lasted a median of 13 months, while overall survival was 23.5 months.

At the end of the trial, eight patients were alive and in active follow-up more than two years after starting rucaparib, four of whom are progression-free.

Rucaparib may also benefit patients with other tumor types, including acinar and squamous cell carcinoma of the pancreas, the researchers said. That could expand the population for which these drugs might be used, they believe.

Of course, because the drug is targeted to certain DNA mutations, genetic screening is key.

The findings "underscore the importance of genetic counseling and testing, which can potentially steer the treatment course in a better direction," study senior author Dr. Susan Domchek said in the release. She is executive director of the Basser Center for BRCA at Penn.

Dr. Wasif Saif is deputy physician-in-chief and medical director at Northwell Health Cancer Institute in Lake Success, N.Y. He wasn't involved in the new trial, but said the rucaparib results echo those of another approved PARP inhibitor drug, olaparib (Lynparza), in terms of effectiveness against pancreatic cancer.

Saif stressed that "the patient population eligible for olaparib or rucaparib maintenance therapy is small," because it's targeted to a narrow subset of tumors. But because pancreatic tumors can be so lethal, "such agents are certainly a welcome addition to the treatment armamentarium," he explained.

The study "underlines the significance of the role of PARP inhibitors in the management of advanced pancreatic cancer and complements the very important patient-related outcomes -- including quality of life, convenience of oral administration, less visits to the cancer center and possibly an advantage in [cost] as well," according to Saif.

More information

For more on pancreatic cancer, see the American Cancer Society.

SOURCES: Wasif Saif, MD, deputy physician-in-chief and medical director, Northwell Health Cancer Institute, Lake Success, N.Y.; University of Pennsylvania, news release, May 10, 2021